ESR1 and breast carcinoma: Among those assays, the 21-gene recurrence score (RS) testing is well-acknowledged and increasingly used for estrogen receptor-positive, human epidermal growth factor receptor-2-negative (ER+/HER2-) breast cancer patients [2].